Latest DRTSW ETF News Today | Earnings, Events & Price Alerts

DRTSW News

Alpha Tau Achieves First Patient Treatment in U.S. Multi-Center Clinical Trial for Pancreatic Cancer

Sep 02 2025Newsfilter

Alpha Tau to Attend Five Investor Conferences in September

Aug 27 2025Newsfilter

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19 2025Newsfilter

Alpha Tau to Participate in May Investor Conferences

May 06 2025Newsfilter

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28 2025Newsfilter

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Feb 24 2025Newsfilter

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27 2025Newsfilter

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 18 2024Newsfilter

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 17 2024Newsfilter

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11 2024Newsfilter

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Dec 06 2024Newsfilter

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 19 2024Newsfilter

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 21 2024Newsfilter

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Oct 10 2024Newsfilter

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 22 2024Newsfilter

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Jun 25 2024Newsfilter

DRTSW

DRTSW

DRTSW News

Alpha Tau Achieves First Patient Treatment in U.S. Multi-Center Clinical Trial for Pancreatic Cancer

Alpha Tau to Attend Five Investor Conferences in September

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&amp;D Update Day

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&amp;D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg&#39;s Oncology Innovators &amp; Investors Symposium

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Acceptance Into FDA&#39;s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild &amp; Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference